|Bid||267.01 x 1100|
|Ask||271.67 x 800|
|Day's Range||268.30 - 269.26|
|52 Week Range||118.11 - 298.76|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||130.41|
|Earnings Date||Nov 24, 2020 - Nov 30, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||304.05|
With thousands of stocks to pick from and a multitude of financial metrics one can use to judge companies' performance and growth potential, how can investors be sure they are making the best possible decisions? For me, "solid" revenue growth means at least 15% year over year, and "sustained" means it has continued for years, not just a few quarters. Since 2016, it has put up annual revenue growth in excess of 45%.
Veeva Systems software has been enlisted to help yet another biotech customer work to develop a possible Covid-19 treatment, far from the first such customer for the Stock of the Day.
Readers who have followed along know that Veeva Systems was one of our original "virus" plays back when the whole pandemic was just reaching U.S. shores, and thus impacting U.S. financial markets, not to mention deeply impacting human lives and families. To refresh, Veeva is not a pharmaceutical, or a biotech. Veeva is a cloud-based software provider that focuses on the life sciences industry.